Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $151 | $77 | $78 | $60 |
| Short-Term Investments | $39 | $51 | $71 | $95 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $8 | $11 | $9 | $9 |
| Total Curr. Assets | $197 | $140 | $157 | $165 |
| Property Plant & Equip (Net) | $12 | $13 | $15 | $16 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $2 | $14 | $31 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $3 | $3 | $3 |
| Total NC Assets | $15 | $18 | $32 | $50 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $213 | $158 | $189 | $215 |
| Liabilities | – | – | – | – |
| Payables | $2 | $1 | $3 | $2 |
| Short-Term Debt | $4 | $4 | $4 | $4 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $17 | $17 | $16 | $11 |
| Total Curr. Liab. | $24 | $22 | $23 | $17 |
| LT Debt | $6 | $7 | $8 | $9 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $6 | $7 | $8 | $9 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $29 | $29 | $31 | $26 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$293 | -$344 | -$313 | -$279 |
| AOCI | -$1 | -$1 | -$1 | -$1 |
| Other Equity | $477 | $474 | $472 | $469 |
| Total Equity | $183 | $129 | $158 | $189 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $213 | $158 | $189 | $215 |
| Net Debt | -$141 | -$66 | -$66 | -$48 |